{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018898","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.082826+00:00","generated_at":"2026-06-02T02:07:50.208915+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harrow Q1 revenue up 33% to $34.6M; net loss widens; FY2024 guidance at least $180M","bullets":["Q1 revenue $34.6M (+33% YoY); GAAP net loss $(13.6M) vs $(6.6M) prior year; adj. EBITDA $0.2M vs $5.3M.","Reaffirms FY2024 revenue guidance of at least $180M, expecting growth with back half stronger.","VEVYE covered lives exceed 150M (from 40M); IHEEZO CMS separate reimbursement confirmed retroactive to Jan 1, 2024.","Signed IHEEZO supply agreements with 7 multi-practice accounts; new patent through 2039. TRIESENCE PPQ batch passing preliminary assays.","Appointed Greg DiPasquale as SVP, Head of Commercial (from Regeneron). Sold Eton shares for $5.5M cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018898","json":"https://secwatch.observer/filing/0001493152-24-018898.json","markdown":"https://secwatch.observer/filing/0001493152-24-018898.md","text":"https://secwatch.observer/filing/0001493152-24-018898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000149315224018898/0001493152-24-018898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000149315224018898/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:07:50.208915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"008f3b3f9fafdf2051a737547afe4bcfcd7a1320","claim":"HARROW, INC. reported the first quarter ended March 31, 2024 results: revenue $34,587,000, net income (13,565,000), EPS (0.38). Guidance reaffirmed.","evidence_excerpt":"First quarter 2024 figures of merit: For the Three Months Ended March 31, 2024 2023 Net revenues $ 34,587,000 $ 26,103,000 Gross margin 69 % 68 % Core gross margin (1) 76 % 76 % Net loss (13,565,000 ) (6,643,000 ) Core net loss (1) (9,789,000 ) (1,042,000 ) Adjusted EBITDA (1) 227,000 5,342,000 Basic and diluted net loss per share (0.38 ) (0.22 )","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1360214/000149315224018898/0001493152-24-018898-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$34,587,000"},{"label":"Net income","value":"(13,565,000)"},{"label":"EPS","value":"(0.38)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}